Emily L Johnson1, Nirma Carballido Martinez2, Eva K Ritzl2. 1. Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA. ejohns92@jhmi.edu. 2. Department of Neurology, The Johns Hopkins School of Medicine, Baltimore, MD, USA.
Abstract
BACKGROUND: Refractory status epilepticus (RSE) is often treated with continuous intravenous medications with the goal of EEG burst suppression. Standard advice is to titrate medications to at least 10-s interburst intervals; however, this has not been shown to improve outcome. We examined EEG characteristics in patients treated with IV anesthetic therapy (IVAT) for RSE to determine which EEG characteristics were associated with successful lifting of IVAT (i.e., without recurrence of status epilepticus). METHODS: We screened the clinical continuous EEG database for adult patients treated with IVAT for RSE (excluding patients with anoxic injury). We measured the length of bursts and interburst intervals for each patient, calculated EEG burst suppression ratios, and graded bursts for the amount of epileptiform activity. We compared these characteristics in successful versus unsuccessful IVAT lifting attempts. RESULTS: We included 17 successful and 20 unsuccessful lifting attempts in 19 patients (5 used as a holdout validation set). The interburst intervals, burst suppression ratios, and length of bursts did not differentiate successful and unsuccessful lifting attempts; the amount of epileptiform activity in bursts correlated with success or failure to wean IVAT (p = 0.008). Maximum burst amplitude <125 μV had 84.6 % sensitivity and 61.1 % specificity for predicting successful lifting. CONCLUSION: The length of interburst intervals and burst suppression did not predict successful termination of RSE in this small cohort. This may suggest that EEG characteristics, rather a strict interburst interval goal, could guide IVAT for RSE.
BACKGROUND: Refractory status epilepticus (RSE) is often treated with continuous intravenous medications with the goal of EEG burst suppression. Standard advice is to titrate medications to at least 10-s interburst intervals; however, this has not been shown to improve outcome. We examined EEG characteristics in patients treated with IV anesthetic therapy (IVAT) for RSE to determine which EEG characteristics were associated with successful lifting of IVAT (i.e., without recurrence of status epilepticus). METHODS: We screened the clinical continuous EEG database for adult patients treated with IVAT for RSE (excluding patients with anoxic injury). We measured the length of bursts and interburst intervals for each patient, calculated EEG burst suppression ratios, and graded bursts for the amount of epileptiform activity. We compared these characteristics in successful versus unsuccessful IVAT lifting attempts. RESULTS: We included 17 successful and 20 unsuccessful lifting attempts in 19 patients (5 used as a holdout validation set). The interburst intervals, burst suppression ratios, and length of bursts did not differentiate successful and unsuccessful lifting attempts; the amount of epileptiform activity in bursts correlated with success or failure to wean IVAT (p = 0.008). Maximum burst amplitude <125 μV had 84.6 % sensitivity and 61.1 % specificity for predicting successful lifting. CONCLUSION: The length of interburst intervals and burst suppression did not predict successful termination of RSE in this small cohort. This may suggest that EEG characteristics, rather a strict interburst interval goal, could guide IVAT for RSE.
Entities:
Keywords:
Burst suppression; Continuous EEG monitoring; EEG; Refractory status epilepticus; Seizures; Status epilepticus
Authors: Andres Fernandez; Hector Lantigua; Christine Lesch; Belinda Shao; Brandon Foreman; J Michael Schmidt; Lawrence J Hirsch; Stephan A Mayer; Jan Claassen Journal: Neurology Date: 2013-12-20 Impact factor: 9.910
Authors: Sara E Hocker; Jeffrey W Britton; Jayawant N Mandrekar; E F M Wijdicks; Alejandro A Rabinstein Journal: JAMA Neurol Date: 2013-01 Impact factor: 18.302
Authors: Eugen Trinka; Hannah Cock; Dale Hesdorffer; Andrea O Rossetti; Ingrid E Scheffer; Shlomo Shinnar; Simon Shorvon; Daniel H Lowenstein Journal: Epilepsia Date: 2015-09-04 Impact factor: 5.864
Authors: Jeannette Hofmeijer; Tim M J Beernink; Frank H Bosch; Albertus Beishuizen; Marleen C Tjepkema-Cloostermans; Michel J A M van Putten Journal: Neurology Date: 2015-06-12 Impact factor: 9.910
Authors: Wolfgang G Muhlhofer; Stephen Layfield; Daniel Lowenstein; Chee Paul Lin; Robert D Johnson; Shalini Saini; Jerzy P Szaflarski Journal: Epilepsia Date: 2019-04-07 Impact factor: 5.864
Authors: Frank A Rasulo; Philip Hopkins; Francisco A Lobo; Pierre Pandin; Basil Matta; Carla Carozzi; Stefano Romagnoli; Anthony Absalom; Rafael Badenes; Thomas Bleck; Anselmo Caricato; Jan Claassen; André Denault; Cristina Honorato; Saba Motta; Geert Meyfroidt; Finn Michael Radtke; Zaccaria Ricci; Chiara Robba; Fabio S Taccone; Paul Vespa; Ida Nardiello; Massimo Lamperti Journal: Neurocrit Care Date: 2022-07-27 Impact factor: 3.532
Authors: Francisco Almeida Lobo; Susana Vacas; Andrea O Rossetti; Chiara Robba; Fabio Silvio Taccone Journal: Best Pract Res Clin Anaesthesiol Date: 2020-10-31
Authors: Daniel B Rubin; Brigid Angelini; Maryum Shoukat; Catherine J Chu; Sahar F Zafar; M Brandon Westover; Sydney S Cash; Eric S Rosenthal Journal: Brain Date: 2020-04-01 Impact factor: 15.255